The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Liver Failure Therapeutics Market Research Report 2024

Global Liver Failure Therapeutics Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1885454

No of Pages : 84

Synopsis
The global Liver Failure Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Liver Failure Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liver Failure Therapeutics.
Report Scope
The Liver Failure Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Liver Failure Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liver Failure Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alfact Innovation
BioLineRx Ltd
Cell2B Advanced Therapeutics SA
Conatus Pharmaceuticals Inc
Immune Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Ocera Therapeutics Inc
PledPharma AB
Promethera Biosciences SA
Silence Therapeutics Plc
Unicyte AG
Ventria Bioscience
Vital Therapies Inc
Segment by Type
Ornithine Phenylacetate
MTL-CEBPA
F-573
BL-1220
PP-100
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liver Failure Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liver Failure Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Ornithine Phenylacetate
1.2.3 MTL-CEBPA
1.2.4 F-573
1.2.5 BL-1220
1.2.6 PP-100
1.2.7 Others
1.3 Market by Application
1.3.1 Global Liver Failure Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liver Failure Therapeutics Market Perspective (2019-2030)
2.2 Liver Failure Therapeutics Growth Trends by Region
2.2.1 Global Liver Failure Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Liver Failure Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Liver Failure Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Liver Failure Therapeutics Market Dynamics
2.3.1 Liver Failure Therapeutics Industry Trends
2.3.2 Liver Failure Therapeutics Market Drivers
2.3.3 Liver Failure Therapeutics Market Challenges
2.3.4 Liver Failure Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liver Failure Therapeutics Players by Revenue
3.1.1 Global Top Liver Failure Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Liver Failure Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Liver Failure Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liver Failure Therapeutics Revenue
3.4 Global Liver Failure Therapeutics Market Concentration Ratio
3.4.1 Global Liver Failure Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liver Failure Therapeutics Revenue in 2023
3.5 Liver Failure Therapeutics Key Players Head office and Area Served
3.6 Key Players Liver Failure Therapeutics Product Solution and Service
3.7 Date of Enter into Liver Failure Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Liver Failure Therapeutics Breakdown Data by Type
4.1 Global Liver Failure Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Liver Failure Therapeutics Forecasted Market Size by Type (2025-2030)
5 Liver Failure Therapeutics Breakdown Data by Application
5.1 Global Liver Failure Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Liver Failure Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Liver Failure Therapeutics Market Size (2019-2030)
6.2 North America Liver Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Liver Failure Therapeutics Market Size by Country (2019-2024)
6.4 North America Liver Failure Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liver Failure Therapeutics Market Size (2019-2030)
7.2 Europe Liver Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Liver Failure Therapeutics Market Size by Country (2019-2024)
7.4 Europe Liver Failure Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liver Failure Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Liver Failure Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Liver Failure Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Liver Failure Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liver Failure Therapeutics Market Size (2019-2030)
9.2 Latin America Liver Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Liver Failure Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Liver Failure Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liver Failure Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Liver Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Liver Failure Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Liver Failure Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alfact Innovation
11.1.1 Alfact Innovation Company Detail
11.1.2 Alfact Innovation Business Overview
11.1.3 Alfact Innovation Liver Failure Therapeutics Introduction
11.1.4 Alfact Innovation Revenue in Liver Failure Therapeutics Business (2019-2024)
11.1.5 Alfact Innovation Recent Development
11.2 BioLineRx Ltd
11.2.1 BioLineRx Ltd Company Detail
11.2.2 BioLineRx Ltd Business Overview
11.2.3 BioLineRx Ltd Liver Failure Therapeutics Introduction
11.2.4 BioLineRx Ltd Revenue in Liver Failure Therapeutics Business (2019-2024)
11.2.5 BioLineRx Ltd Recent Development
11.3 Cell2B Advanced Therapeutics SA
11.3.1 Cell2B Advanced Therapeutics SA Company Detail
11.3.2 Cell2B Advanced Therapeutics SA Business Overview
11.3.3 Cell2B Advanced Therapeutics SA Liver Failure Therapeutics Introduction
11.3.4 Cell2B Advanced Therapeutics SA Revenue in Liver Failure Therapeutics Business (2019-2024)
11.3.5 Cell2B Advanced Therapeutics SA Recent Development
11.4 Conatus Pharmaceuticals Inc
11.4.1 Conatus Pharmaceuticals Inc Company Detail
11.4.2 Conatus Pharmaceuticals Inc Business Overview
11.4.3 Conatus Pharmaceuticals Inc Liver Failure Therapeutics Introduction
11.4.4 Conatus Pharmaceuticals Inc Revenue in Liver Failure Therapeutics Business (2019-2024)
11.4.5 Conatus Pharmaceuticals Inc Recent Development
11.5 Immune Pharmaceuticals Inc
11.5.1 Immune Pharmaceuticals Inc Company Detail
11.5.2 Immune Pharmaceuticals Inc Business Overview
11.5.3 Immune Pharmaceuticals Inc Liver Failure Therapeutics Introduction
11.5.4 Immune Pharmaceuticals Inc Revenue in Liver Failure Therapeutics Business (2019-2024)
11.5.5 Immune Pharmaceuticals Inc Recent Development
11.6 Mina Therapeutics Ltd
11.6.1 Mina Therapeutics Ltd Company Detail
11.6.2 Mina Therapeutics Ltd Business Overview
11.6.3 Mina Therapeutics Ltd Liver Failure Therapeutics Introduction
11.6.4 Mina Therapeutics Ltd Revenue in Liver Failure Therapeutics Business (2019-2024)
11.6.5 Mina Therapeutics Ltd Recent Development
11.7 Mylan NV
11.7.1 Mylan NV Company Detail
11.7.2 Mylan NV Business Overview
11.7.3 Mylan NV Liver Failure Therapeutics Introduction
11.7.4 Mylan NV Revenue in Liver Failure Therapeutics Business (2019-2024)
11.7.5 Mylan NV Recent Development
11.8 Ocera Therapeutics Inc
11.8.1 Ocera Therapeutics Inc Company Detail
11.8.2 Ocera Therapeutics Inc Business Overview
11.8.3 Ocera Therapeutics Inc Liver Failure Therapeutics Introduction
11.8.4 Ocera Therapeutics Inc Revenue in Liver Failure Therapeutics Business (2019-2024)
11.8.5 Ocera Therapeutics Inc Recent Development
11.9 PledPharma AB
11.9.1 PledPharma AB Company Detail
11.9.2 PledPharma AB Business Overview
11.9.3 PledPharma AB Liver Failure Therapeutics Introduction
11.9.4 PledPharma AB Revenue in Liver Failure Therapeutics Business (2019-2024)
11.9.5 PledPharma AB Recent Development
11.10 Promethera Biosciences SA
11.10.1 Promethera Biosciences SA Company Detail
11.10.2 Promethera Biosciences SA Business Overview
11.10.3 Promethera Biosciences SA Liver Failure Therapeutics Introduction
11.10.4 Promethera Biosciences SA Revenue in Liver Failure Therapeutics Business (2019-2024)
11.10.5 Promethera Biosciences SA Recent Development
11.11 Silence Therapeutics Plc
11.11.1 Silence Therapeutics Plc Company Detail
11.11.2 Silence Therapeutics Plc Business Overview
11.11.3 Silence Therapeutics Plc Liver Failure Therapeutics Introduction
11.11.4 Silence Therapeutics Plc Revenue in Liver Failure Therapeutics Business (2019-2024)
11.11.5 Silence Therapeutics Plc Recent Development
11.12 Unicyte AG
11.12.1 Unicyte AG Company Detail
11.12.2 Unicyte AG Business Overview
11.12.3 Unicyte AG Liver Failure Therapeutics Introduction
11.12.4 Unicyte AG Revenue in Liver Failure Therapeutics Business (2019-2024)
11.12.5 Unicyte AG Recent Development
11.13 Ventria Bioscience
11.13.1 Ventria Bioscience Company Detail
11.13.2 Ventria Bioscience Business Overview
11.13.3 Ventria Bioscience Liver Failure Therapeutics Introduction
11.13.4 Ventria Bioscience Revenue in Liver Failure Therapeutics Business (2019-2024)
11.13.5 Ventria Bioscience Recent Development
11.14 Vital Therapies Inc
11.14.1 Vital Therapies Inc Company Detail
11.14.2 Vital Therapies Inc Business Overview
11.14.3 Vital Therapies Inc Liver Failure Therapeutics Introduction
11.14.4 Vital Therapies Inc Revenue in Liver Failure Therapeutics Business (2019-2024)
11.14.5 Vital Therapies Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’